EBM & Clinical Trials
Science family of journals announces change to open-access policy
20 Jan, 2021 | 01:23h | UTCScience family of journals announces change to open-access policy – Nature
See also: A new mandate highlights costs, benefits of making all scientific articles free to read – Science
Related: Open-access Science Funders Announce Price Transparency Rules for Publishers (several resources on the subject)
Opinion: A big science publisher is going open access. But at what cost?
19 Jan, 2021 | 01:35h | UTCOpinion: A Big Science Publisher Is Going Open Access. But at What Cost? – Undark
Related: A new mandate highlights costs, benefits of making all scientific articles free to read – Science AND Open-access Science Funders Announce Price Transparency Rules for Publishers (several resources on the subject) AND For €9500, Nature journals will now make your paper free to read
Designing and undertaking randomized implementation trials: guide for researchers
19 Jan, 2021 | 01:20h | UTCDesigning and undertaking randomised implementation trials: guide for researchers – The BMJ
Commentary on Twitter
Despite the need for high quality evidence from implementation research, randomised trials of implementation strategies often have serious limitations. This article aims to provide a best practice guide to randomised implementation trialshttps://t.co/CqTvhsINPv
— The BMJ (@bmj_latest) January 18, 2021
A new mandate highlights costs, benefits of making all scientific articles free to read
15 Jan, 2021 | 08:30h | UTCA new mandate highlights costs, benefits of making all scientific articles free to read – Science
Related: Open-access Science Funders Announce Price Transparency Rules for Publishers (several resources on the subject)
ATS Research Statement: Informing healthcare decisions with observational research assessing causal effect
14 Jan, 2021 | 01:43h | UTC
Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response
13 Jan, 2021 | 02:10h | UTC
Commentaries on Twitter
New paper via our PREVENT Group w 22 concrete recs that provide a roadmap for the ethically responsible, socially just, & respectful inclusion of the interests of pregnant women in the development & deployment of vaccines against emerging pathogens. https://t.co/tp6gt20dh0
— Ruth Faden (@fadenethx) May 6, 2019
Infectious disease outbreaks can severely affect the health interests of pregnant women and their babies. PREVENT's guidance promotes the inclusion of pregnant women in the development and deployment of vaccines against emerging pathogens ➡️ https://t.co/P8IKXCU8tI pic.twitter.com/LYDHfQ2f9y
— CEPI (@CEPIvaccines) May 13, 2019
Blueprint for cancer research: Critical gaps and opportunities
13 Jan, 2021 | 01:36h | UTCBlueprint for cancer research: Critical gaps and opportunities – CA: A Cancer Journal for Clinicians
Managing conflicts of interest in the development of health guidelines
12 Jan, 2021 | 01:41h | UTCRelated Guidance: Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines – Annals of Internal Medicine
Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—we need more details and the raw data
10 Jan, 2021 | 20:48h | UTC
Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action
18 Dec, 2020 | 09:52h | UTCCommentaries: Pregnant women excluded from three-quarters of COVID-19 treatment trials – The Lancet AND Expert reaction to opinion piece on pregnant women and COVID-19 treatment trials – Science Media Centre
Commentary on Twitter (thread – click for more)
NEW—Pregnant women are among those most in need of safe and effective therapies against #COVID19, but are routinely excluded from 3/4 of treatment trials. Read the review published in @LancetGH: https://t.co/xvBfHqnHMe @WHO pic.twitter.com/pBuTcsUZ0O
— The Lancet (@TheLancet) December 17, 2020
Publication bias: a problem that leaves us without the full picture on the benefits and harms of treatments
18 Dec, 2020 | 09:37h | UTC
Commentary on Twitter
Publication bias: a problem that leaves us without the full picture on the benefits & harms of treatments https://t.co/ShKZLEiXiv The last blog in @CochraneUK's special series explores why publication bias is so problematic for people making decisions about health care. #OhReally pic.twitter.com/isS1eT4ObZ
— Students4BE (@Students4BE) December 17, 2020
Scientists fear that ‘covidization’ is distorting research: Some researchers worry that shifting priorities towards pandemic-focused science comes at the expense of other disciplines.
17 Dec, 2020 | 08:47h | UTCScientists fear that ‘covidization’ is distorting research – Nature
How a torrent of COVID science changed research publishing — in seven charts
17 Dec, 2020 | 08:48h | UTCHow a torrent of COVID science changed research publishing — in seven charts – Nature
2021: research and medical trends in a post-pandemic world
17 Dec, 2020 | 08:46h | UTC2021: research and medical trends in a post-pandemic world – Nature
Open-access journal eLife announces ‘preprint first’ publishing model
16 Dec, 2020 | 09:53h | UTCOpen-access journal eLife announces ‘preprint first’ publishing model – Nature
Nature’s 10: ten people who helped shape science in 2020
16 Dec, 2020 | 09:52h | UTCNature’s 10: ten people who helped shape science in 2020 – Nature
Perspective: How Science Beat the Virus – And what it lost in the process
15 Dec, 2020 | 01:40h | UTCHow Science Beat the Virus – The Atlantic
Commentary from the author on Twitter (thread – click for more)
🚨I wrote the Atlantic’s next cover story on the COVIDization of science. No other disease has been scrutinized so intensely, by so much combined intellect, in so brief a time. This piece is about both the victories achieved & the weaknesses exposed. 1/ https://t.co/RbL9mVHhEv
— Ed Yong (@edyong209) December 14, 2020
Systematic Review: Financial conflicts of interest are associated with favorable recommendations of drugs and devices in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews
11 Dec, 2020 | 09:18h | UTC
Just published: AstraZeneca-Oxford Covid-19 vaccine shows moderate efficacy, but questions remain about the most effective dosing regimen
9 Dec, 2020 | 08:25h | UTCCommentaries: Oxford COVID vaccine paper highlights lingering unknowns about results – Nature AND Detailed data on AstraZeneca-Oxford Covid-19 vaccine show it has moderate efficacy – STAT AND Oxford–AstraZeneca COVID-19 vaccine efficacy – The Lancet AND Oxford COVID-19 vaccine is safe and protects against disease, first published results from phase 3 trials – The Lancet AND Expert reaction to a study on the results of phase 3 human trials of the Oxford/AZ COVID-19 vaccine – Science Media Centre
New vaccine data is coming: Watch out for these 3 claims
9 Dec, 2020 | 08:17h | UTCNew Vaccine Data Is Coming: Watch Out for These 3 Claims – Wired
Opinion: “Get ready for vaccine false side effects”. When millions of people are vaccinated, naturally occurring health problems could be wrongly attributed to vaccines
8 Dec, 2020 | 07:55h | UTCGet Ready for False Side Effects – Science Translational Medicine
First-of-its-kind African trial tests common drugs to prevent severe COVID-19. “Could cheap, widely available drugs prevent patients with mild illness from becoming severely sick?”
8 Dec, 2020 | 07:46h | UTCFirst-of-its-kind African trial tests common drugs to prevent severe COVID-19 – Science
How to write a superb literature review
8 Dec, 2020 | 07:32h | UTCHow to write a superb literature review – Nature
Opinion: “Put an end to publication by proclamation for Covid vaccines”
2 Dec, 2020 | 07:27h | UTCPut An End To Publication By Proclamation For Covid Vaccines – Forbes
Opinion: How Prestige Journals Remain Elite, Exclusive and Exclusionary. “by announcing a €9,500 price tag, Nature has failed to enact their own diversity and inclusion pledge”
1 Dec, 2020 | 08:22h | UTCHow Prestige Journals Remain Elite, Exclusive And Exclusionary – Forbes
See also: For €9500, Nature journals will now make your paper free to read